LSD Clinical Trials: Global Phase 3 Efforts and Evidence Gaps
A 2026 scoping review reveals a surge in LSD research for pain and neuropsychiatric disorders, mapping 51 trials and highlighting the urgent need for robust phase 2 and 3 data, especially for microdosing.
Global Surge in LSD Clinical Trials: Key Findings from 2026 Review
A 2026 scoping review published via OpenAlex (source) systematically maps 51 clinical trials investigating lysergic acid diethylamide (LSD) for pain and neuropsychiatric disorders, revealing a marked increase in research activity since 2014. The review identifies three ongoing phase 3 trials and a predominance of early-phase studies, reflecting both renewed scientific interest and persistent regulatory caution. The most common indications under investigation include major depressive disorder (MDD), anxiety disorders, cluster headache, alcohol use disorder, ADHD, premenstrual disorders, and palliative care-related distress. Switzerland leads in trial activity, followed by the United States, the Netherlands, and Australia/New Zealand. Most studies are randomized controlled trials (RCTs) using inactive placebos, with a typical dosage of 100 micrograms (µg) of LSD.
Mechanisms, Early Outcomes, and the Microdosing Puzzle
LSD's mechanism of action involves potent agonism at the 5-HT2A serotonin receptor, which is hypothesized to drive its psychoactive and potential therapeutic effects. Published phase 1 and 2 trials show early signals of benefit for anxiety and depression, echoing findings from mid-20th-century research but now using modern trial designs and endpoints. However, the review highlights that microdosing—sub-perceptual administration of LSD, often at 10–20 µg—has not demonstrated consistent efficacy. Results across microdosing studies are highly variable, possibly due to differences in dosing protocols, subjective reporting, and lack of standardized outcome measures. This inconsistency complicates both clinical translation and regulatory evaluation, as microdosing remains popular in public discourse but lacks robust supporting data.
Policy and Research Implications: The Need for Rigorous Phase 2 and 3 Data
The review's mapping of trial phases and geographies underscores a critical bottleneck: most LSD studies remain in early phases, with only three phase 3 trials currently underway. This evidentiary gap limits the ability of regulators, such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), to evaluate LSD for formal indications. Notably, the review finds that many trials are investigator-initiated and rely on academic or philanthropic funding, rather than industry sponsors, which may slow progress toward regulatory approval. For sponsors and researchers, the review provides a concrete roadmap for future trial design—highlighting the need for larger, multi-site, placebo-controlled studies with standardized dosing and endpoints, especially for microdosing protocols. A non-obvious insight from the review is that heterogeneity in trial sponsorship and site infrastructure has led to divergent data quality, complicating meta-analysis and cross-study comparison.
Risks, Uncertainties, and the Path Forward
LSD remains a Schedule I substance in many jurisdictions, posing legal and logistical challenges for trial conduct and patient access. The review notes that while adverse events in controlled settings are generally mild and transient (e.g., anxiety, transient confusion), the lack of long-term safety data—especially for repeated or microdose regimens—remains a significant concern. Furthermore, the review cautions that early positive signals for anxiety and depression are based on small sample sizes and may not generalize to broader populations. The inconsistent findings in microdosing studies highlight a real failure mode: underpowered trials with heterogeneous protocols risk generating noise rather than actionable evidence, which could ultimately delay or derail regulatory pathways.
Conclusion: Strategic Priorities for the Next Phase of LSD Research
The 2026 scoping review provides a comprehensive snapshot of the global LSD clinical trial landscape, mapping both progress and persistent gaps. For the field to advance, stakeholders must prioritize robust phase 2 and 3 trials with harmonized protocols, transparent reporting, and meaningful clinical endpoints. As regulatory agencies and sponsors consider the next steps, the review serves as both a warning and a guide: without rigorous, coordinated research, the promise of LSD for neuropsychiatric and pain disorders will remain speculative. The coming years will test whether the field can overcome these challenges and deliver definitive answers for patients, clinicians, and policymakers.
By Dr. Alex Morgan, PhD (Neuropharmacology). How we research: Reviewed by Dr. Alex Morgan on 2026-11-21. Primary sources: OpenAlex, ClinicalTrials.gov, PubMed, ANZCTR, Netherlands Trial Registry.
Get tomorrow's briefing in your inbox
Policy, research, and regulatory signal — delivered on our publish cadence.